<DOC>
	<DOC>NCT02669940</DOC>
	<brief_summary>This study seeks to assess the effectiveness, patient reported outcomes, work productivity and healthcare resource utilization of the interferon-free regimen of Paritaprevir (PTV)/ritonavir (r) - Ombitasvir (OBV), ± Dasabuvir (DSV), ± Ribavirin in chronic hepatitis C (CHC) participants in a real life setting across clinical practice populations.</brief_summary>
	<brief_title>Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Patients are eligible for observation in this cohort if the following applies: Treatmentnaïve or experienced adult male or female patients with confirmed CHC, genotype 1, receiving combination therapy with the interferonfree ABBVIE REGIMEN ± RBV according to standard of care and in line with the current local label If RBV is coadministered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label (with special attention to contraception requirements and contraindication during pregnancy) Patients must voluntarily sign and date informed consent prior to inclusion into the study Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial Patient must not be participating or intending to participate in a concurrent interventional therapeutic trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Ombitasvir</keyword>
	<keyword>Dasabuvir</keyword>
	<keyword>Paritaprevir</keyword>
</DOC>